Patents by Inventor Gordon J. Freeman

Gordon J. Freeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220289854
    Abstract: The present invention relates, in part, to methods of treating cancers using combinations of anti-CX3CR1 and anti-immune checkpoint therapies.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 15, 2022
    Inventors: Gordon J. Freeman, Apoorvi Chaudhri
  • Patent number: 11359020
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 14, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Patent number: 11261251
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 1, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Publication number: 20220041726
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 10, 2022
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • Publication number: 20220033502
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 3, 2022
    Inventors: Gordon J. Freeman, Yanping Xiao
  • Patent number: 11220545
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 11, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Yanping Xiao
  • Patent number: 11207393
    Abstract: The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 28, 2021
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Arlene H. Sharpe, Gordon J. Freeman, Loise M. Francisco, Peter T. Sage, Sun J. Lee, Scott B. Lovitch, Vikram R. Juneja, Catherine L. Tan
  • Patent number: 11124569
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 21, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard College, Emory University
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • Patent number: 11116818
    Abstract: The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by T-cell Immunoglobulin and Mucin-domain containing proteins (TIM proteins) and other phosphatidylserine receptors.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 14, 2021
    Assignee: Children's Medical Center Corporation Dana-Farber Cancer Institute
    Inventors: Hyeryun Choe, Stephanie Jemielity, Dale T. Umetsu, Rosemarie H. De Kruyff, Gordon J. Freeman
  • Publication number: 20210267991
    Abstract: The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 2, 2021
    Inventors: Jean Zhao, Johann Bergholz, Gordon J. Freeman, Thomas M. Roberts
  • Publication number: 20210115144
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies, and antigen-binding fragments thereof, that specifically bind to HHLA2, as well as immunoglobulins, polypeptides, and nucleic acids thereof, and methods of using such antibodies for diagnosis, prognostic, and therapeutic purposes.
    Type: Application
    Filed: April 5, 2019
    Publication date: April 22, 2021
    Inventors: Gordon J. Freeman, Antonio R. Arulanandam
  • Patent number: 10960008
    Abstract: The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: March 30, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jean Zhao, Johann Bergholz, Gordon J. Freeman, Thomas M. Roberts
  • Patent number: 10948492
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness of esophagogastric cancers to inhibitors of the PD-1 pathway.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adam Bass, Sarah Derks, Gordon J. Freeman, Scott J. Rodig
  • Patent number: 10934353
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 2, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Publication number: 20210032334
    Abstract: The present invention relates, in part, to methods of treating cancers using combinations of anti-BTNL2 and anti-immune checkpoint therapies.
    Type: Application
    Filed: February 27, 2019
    Publication date: February 4, 2021
    Inventors: Gordon J. Freeman, Yanping Xiao
  • Publication number: 20200172616
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: July 9, 2019
    Publication date: June 4, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Publication number: 20200115452
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 16, 2020
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Straus
  • Publication number: 20200095325
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 26, 2020
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Publication number: 20190375818
    Abstract: The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.
    Type: Application
    Filed: March 27, 2019
    Publication date: December 12, 2019
    Inventors: F. Stephen Hodi, Jun Zhou, Gordon J. Freeman, Jingjing Li, Xinqi Wu
  • Publication number: 20190330350
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Application
    Filed: December 10, 2018
    Publication date: October 31, 2019
    Inventors: Gordon J. Freeman, Arlene H. Sharpe